Trial Profile
Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Lira-1
- 07 Jun 2022 Results of post-hoc analysis assessing the effect of adjunctive therapy with the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide on eGDR in patients with type 1 diabetes presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 15 Sep 2017 Results assessing the effect of liraglutide treatment on autonomic nervous system function presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results of effects of liraglutide-induced weight loss on BMD and bone turnover presented at the 77th Annual Scientific Sessions of the American Diabetes Association